Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 6

A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications

Authors Behzad Molavi, Negah Rassouli, Suveer Bagwe, Neda Rasouli

Published 15 January 2008 Volume 2007:3(6) Pages 967—973

Behzad Molavi1, Negah Rassouli2, Suveer Bagwe1, Neda Rasouli2

Central Arkansas Veterans Healthcare System and University of Arkansas for Medical sciences, 1Division of cardiology and 2Division of Endocrinology, College of Medicine, Little Rock, Arkansas, USA

Abstract: The rising incidence of obesity and insulin resistance to epidemic proportions has closely paralleled the surge in the prevalence of diabetes and outpaced therapeutic advances in diabetes prevention and treatment. Current evidence points to obesity induced oxidative stress and chronic inflammation as the common denominators in the evolution of insulin resistance and diabetes. Of all the hypoglycemic agents in the pharmacological arsenal against diabetes, thiazolidinediones, in particular pioglitazone, as well as metformin appear to have additional effects in ameliorating oxidative stress and inflammation; rendering them attractive tools for prevention of insulin resistance and diabetes. In addition to their hypoglycemic and lipid modifying properties, pioglitazone and metformin have been shown to exert anti-oxidative and anti-inflammatory effects in vascular beds, potentially slowing the accelerated atherosclerosis in diabetes, which is the major cause of morbidity and mortality in the affected population. The combination of pioglitazone and metformin would thus appear to be an effective pharmacological intervention in prevention and treatment of diabetes. Finally, this review will address the currently available evidence on diabetic cardiomyopathy and the potential role of combination therapy with pioglitazone and metformin.

Keywords: insulin resistance, oxidative stress, inflammation, pioglitazone, metformin, atherosclerosis, diabetic cardiomyopathy

Download Article [PDF] 

Readers of this article also read:

Functionalization of ethylene vinyl acetate with antimicrobial chlorhexidine hexametaphosphate nanoparticles

Wood NJ, Maddocks SE, Grady HJ, Collins AM, Barbour ME

International Journal of Nanomedicine 2014, 9:4145-4152

Published Date: 27 August 2014

Linagliptin as add-on therapy to insulin for patients with type 2 diabetes

von Websky K, Reichetzeder C, Hocher B

Vascular Health and Risk Management 2013, 9:681-694

Published Date: 1 November 2013

Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance

El-Helou N, Al-Hajje A, Ajrouche R, Awada S, Rachidi S, Zein S, Salameh P

Vascular Health and Risk Management 2013, 9:81-88

Published Date: 1 March 2013

Evaluation of the genotoxicity of cellulose nanofibers

de Lima R, Feitosa LO, Maruyama CR, Barga MA, Yamawaki PC, Vieira IJ, Teixeira EM, Corrêa AC, Mattoso LH, Fraceto LF

International Journal of Nanomedicine 2012, 7:3555-3565

Published Date: 11 July 2012

Acoustic cardiac signals analysis: a Kalman filter–based approach

Salleh SH, Hussain HS, Swee TT, Ting CM, Noor AM, Pipatsart S, Ali J, Yupapin PP

International Journal of Nanomedicine 2012, 7:2873-2881

Published Date: 11 June 2012

Reduction of C-reactive protein and the use of anti-hypertensives

Carmine Savoia, Ernesto L Schiffrin

Vascular Health and Risk Management 2007, 3:975-983

Published Date: 15 January 2008

Management of intracerebral hemorrhage

Ramandeep Sahni, Jesse Weinberger

Vascular Health and Risk Management 2007, 3:701-709

Published Date: 15 November 2007

Macro- and micronutrients in patients with congestive heart failure, particularly African-Americans

Kevin P Newman, Syamal K Bhattacharya, Ahmad Munir, Richard C Davis, Judith E Soberman, et al

Vascular Health and Risk Management 2007, 3:743-747

Published Date: 15 November 2007

Mirtazapine in the treatment of essential tremor: an open-label, observer-blind study

Davide Uccellini, G Grampa, I La Spina, D Nasuelli, I Neromante, L Politini, F Reverberi, D Porazzi, V Carli, G Camardese

Neuropsychiatric Disease and Treatment 2006, 2:95-100

Published Date: 15 March 2006